Understanding Prior Authorization in Sleep Medicine Sleep medicine practices routinely navigate prior authorization requirements for diagnostics such as home sleep apnea testing (HSAT) and in-lab polysomnography (PSG), as well as …
Sleep Apnea
-
-
The Rising Cost of Weight Management and Specialty Drugs: Impact on Private Health Plans Private drug plans are facing a significant financial shift as the cost of weight management medications …
-
Central Sleep Apnea vs. Obstructive Sleep Apnea: Understanding the Key Differences If you’ve ever woken up gasping for air or spent your day feeling like your brain is stuck in …
-
Obstructive Sleep Apnea Linked to Increased Cancer Risk and Mortality, Research Suggests Novel research indicates a significant link between obstructive sleep apnea (OSA) and an increased risk of cancer, its …
-
Man Loses Over 100 Pounds After Sleep Apnea Diagnosis, Leg Infection Scare A 55-year-old man from Bury St. Edmunds, England, dramatically improved his health after losing 108 pounds (approximately 49 …
-
Dramatic Weight Loss and Sleep Apnea Relief: A Man’s Journey from 178kg to 70kg A British man experienced a remarkable transformation, losing 108kg after a leg injury prompted a lifestyle …
-
GLP-1 Weight Loss Drugs: Many Patients Restart or Switch Therapies After Stopping A recent study indicates that many individuals who discontinue glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight …
-
Why Do I Drool in My Sleep? Causes, Concerns, and When to See a Doctor Waking up with a wet spot on your pillow can be unsettling, but drooling during …
-
GLP-1 Receptor Agonists: A New Era in Metabolic and Cardiovascular Health A sweeping review published in The Lancet reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, …
-
New clinical trial evidence suggests targeting both obesity and sleep-disordered breathing together may reshape cardiometabolic risk management in obstructive sleep apnea. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes …